Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Horizon Therapeutics (NQ: HZNP ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Horizon Therapeutics < Previous 1 2 ... 10 11 12 13 14 15 16 17 Next > New Analysis of UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in Neurology Neuroimmunology & Neuroinflammation May 06, 2021 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc Announces Elizabeth H.Z. Thompson as a Healthcare Businesswomen’s Association 2021 Luminary May 06, 2021 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics PLC (HZNP) Q1 2021 Earnings Call Transcript May 05, 2021 HZNP earnings call for the period ending March 31, 2021. Via The Motley Fool Topics Earnings Exposures Financial Horizon Earnings Miss, Revenue Tops May 05, 2021 Horizon Therapeutics earnings fell short of Q1 estimates though revenue beat views. The biotech raised its 2021 revenue target. Via Investor's Business Daily Topics Earnings Exposures Financial Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge May 01, 2021 Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... Via Benzinga Exposures Product Safety The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues May 05, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... Via Benzinga Recap: Horizon Therapeutics Q1 Earnings May 05, 2021 Shares of Horizon Therapeutics (NASDAQ:HZNP) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were down 92.50% year over year to $... Via Benzinga Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Net Sales Guidance and Full-Year Adjusted EBITDA Guidance to Incorporate Recently Acquired Viela Bio, Inc. May 05, 2021 From Horizon Therapeutics plc Via Business Wire Biotech Cel-Sci Stock Joins Rank Of Stocks With RS Ratings Over 90 April 28, 2021 Cel-Sci shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. Via Investor's Business Daily Biotech Applied Molecular Transport Stock Earns Relative Strength Rating Upgrade April 27, 2021 On Tuesday, Applied Molecular Transport stock reached an important technical milestone, seeing its Relative Strength Rating jump to 91 from 87. Via Investor's Business Daily The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx April 29, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... Via Benzinga Horizon Therapeutics plc Ranks Among the Top Companies in Overall Corporate Reputation in 2020 PatientView Survey of Patient Organizations Worldwide April 27, 2021 From Horizon Therapeutics plc Via Business Wire The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout April 27, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 26) 10x Genomics, Inc. (NASDAQ... Via Benzinga Topics Intellectual Property Exposures Intellectual Property 3 Reasons to Buy Horizon Therapeutics Stock and 1 Not To April 17, 2021 Horizon Therapeutics's shares are up almost 200% over the past 12 months, buoyed by mind-boggling sales of its new blockbuster drug. Via The Motley Fool New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD) April 16, 2021 From Horizon Therapeutics Via Business Wire New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology April 16, 2021 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For® April 12, 2021 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc to Release First-Quarter 2021 Financial Results and Host Webcast on May 5, 2021 April 08, 2021 From Horizon Therapeutics plc Via Business Wire RECIPE Randomized Controlled Trial Data Published in Arthritis & Rheumatology Show Higher Response Rates Using KRYSTEXXA® (pegloticase injection) with the Immunomodulator Mycophenolate Mofetil April 07, 2021 From Horizon Therapeutics plc Via Business Wire Does 2021's Best Biopharma to Work for Belong in Your Portfolio? April 07, 2021 Horizon Therapeutics has a clear path to significant sales growth. Via The Motley Fool < Previous 1 2 ... 10 11 12 13 14 15 16 17 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.